7 rezultatov
An evaluation is given of the shortcomings of existing oral fluid therapies and their consequences: lack of protection of the intestinal wall and the supply of unabsorbed carbohydrates to the large intestine. The inclusion of specific mucopolysaccharides having a polyxylose backbone and galactose
Sanfilippo A syndrome, mucopolysaccharidosis type IIIA, is caused by a deficiency of heparan sulphamidase activity, and usually presents in childhood with neurodegeneration leading to death in teenage years. Visceral symptoms are limited to coarsening and diarrhea. We now describe an adult patient
Vitamin A decreased the urinary excretion of total mucopolysaccharides in a patient with Hurler-Scheie compound (type IH-S mucopolysaccharidosis). Vitamin A was administered orally in daily doses of 1,000 to 2,000 IU/kg body weight for 10 years. Adverse clinical responses such as irritability, bone
Intestinal lesions caused by a calf diarrheal reovirus-like agent were studied by scanning electron microscopy, light microscopy, and immunofluorescent microscopy in 2 gnotobiotic calves inoculated per orum. The calves were euthanatized 6 hours after the onset of diarrhea. Villi in the cranial and
In a screening program in Cincinnati urine specimens from over 20,000 infants and children were tested for inherited metabolic disorders involving amino acids, carbohydrates, phenolic acids, organic acids, keto acids, mucopolysaccharides, and imidazoles. The subjects were selected on the basis of
The carbazole, C-5720, has the same order of analgesic, antipyretic and anti-inflammatory activity as indomethacin and is more potent than phenylbutazone and acetylsalicylic acid in the yeast inflamed paw, the carrageenin foot edema, the Mycobacterium butyricum-induced pyrexia, and the acute and
Objectives Sanfilippo syndrome (Mucopolysaccharidosis III, MPS III) is a rare autosomal recessive hereditary disease, which is caused by lysosomal enzyme deficiency. This study was operated to investigate clinical and molecular characteristics of patients with MPS III, which will improve the